Get the Stockscreener App
13.73
0.07%
0.010
After Hours:
13.73
Organon Co stock is traded at $13.73, with a volume of 1.39M.
It is up +0.07% in the last 24 hours and down -0.15% over the past month.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
See More
Previous Close:
$13.72
Open:
$13.74
24h Volume:
1.39M
Relative Volume:
0.53
Market Cap:
$3.61B
Revenue:
$6.16B
Net Income/Loss:
$246.00M
P/E Ratio:
14.63
EPS:
0.9387
Net Cash Flow:
$708.00M
1W Performance:
+0.37%
1M Performance:
-0.15%
6M Performance:
+125.08%
1Y Performance:
+35.67%
1-Day Range:
$13.70
$13.74
1-Week Range:
$13.67
$13.76
52-Week Range:
$5.69
$13.79
Organon Co Stock (OGN) Company Profile
Name
Organon Co
Sector
Industry
Phone
551-430-6000
Address
30 HUDSON STREET, JERSEY CITY
Compare OGN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
13.73 | 3.61B | 6.16B | 246.00M | 708.00M | 0.9387 |
LLY
Lilly Eli Co
|
1,183.46 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
271.22 | 653.61B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
264.34 | 467.12B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
148.78 | 367.07B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
145.46 | 276.48B | 54.66B | 13.58B | 16.05B | 7.0171 |
Organon Co Stock (OGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Underweight |
| Oct-27-25 | Downgrade | Piper Sandler | Overweight → Underweight |
| May-02-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-06-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-03-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-21-23 | Initiated | Barclays | Overweight |
| Mar-16-23 | Initiated | Raymond James | Outperform |
| Oct-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-06-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-07-21 | Initiated | Piper Sandler | Neutral |
| Sep-01-21 | Initiated | BofA Securities | Buy |
| Jul-22-21 | Initiated | Citigroup | Buy |
| Jun-15-21 | Initiated | JP Morgan | Neutral |
| Jun-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-10-21 | Initiated | Evercore ISI | Outperform |
View All
Organon Co Stock (OGN) Latest News
Organon & Co. (OGN) Stock Forecasts - Yahoo! Finance Canada
Sun Pharma’s Biggest Global Bet, Buys Organon in $11.75 Billion Deal; Pharma Stock Surge 7%Time to Buy? - goodreturns.in
Organon & Co. (OGN) Stock forecasts - Yahoo Finance Singapore
Precision Trading with Organon & Co. (OGN) Risk Zones - Stock Traders Daily
Why Organon (OGN) Is Getting Attention Today - Yahoo Finance
Organon (OGN) Wins FDA Review Acceptance For Its Hormone Free Contraceptive Device - Yahoo Finance
Is Trending Stock Organon & Co. (OGN) a Buy Now? - Yahoo Finance
Organon (OGN) Looks 22% Overvalued Following The MIUDELLA FDA Filing - simplywall.st
Class A Dig — Organon/Sun Pharma premature-close (May ACQ deleted; early-2027 expected) - Dealroom.co
Organon (OGN) Wins FDA Review Acceptance For New Hormone Free Contraceptive - simplywall.st
how InvestingPro spotted Organon’s 65% gain in healthcare sector By Investing.com - Investing.com Canada
Organon Backs Women’s Health Efforts Across India - pharmacy.biz
Organon Korea, Boryung expand Atozet tie-up to co-promotion - Korea Biomedical Review
Organon & Co. Common Stock (NY: OGN - The Chronicle-Journal
ORGANON & CO.MIUDELLA ANTICIPATED TO BE COMMERCIALLY AVAILABLE IN LATE 2026 - Moomoo
Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA - Business Wire
Responsive Playbooks and the OGN Inflection - Stock Traders Daily
Organon: A Merger-Arbitrage Hold With Limited Upside - Seeking Alpha
OGN Stock Set For Blastoff? Sun Pharma Offers 24% Premium In All-Cash Buyout Deal - Stocktwits
Sun Pharma Gets Investment-Grade Ratings From Moody's, S&P for USD 11.75 Bn Organon Deal - Medical Dialogues
Sun Pharma gets ratings boost from Moody's, S&P over $11.75-bn Organon bid - Business Standard
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Sun Pharma receives ratings boost over USD 11.75-billion Organon acqui - Daily Pioneer
Sun Pharma Gets Ratings Boost From Moody's, S&P Over $11.75-Bn Organon & Co Acquisition Bid - outlookbusiness.com
Sun Pharma gets ratings boost from Moody's, S&P over ₹11.75-billion Organon & Co acquisition bid - BusinessLine
Sun Pharma gets ratings boost from Moody's, S&P over $11.75 bn Organon & Co acquisition bid - ET Manufacturing
Sun Pharma gets ratings boost from Moody's, S&P over USD 11.75-bn Organon & Co acquisition bid - The Economic Times
Sun Pharma Gets Ratings Boost After Organon Acquisition Bid - Rediff MoneyWiz
Organon & Co. (OGN) Edges Up 0.15% to $13.78 as Shares Trade Between Key Support and ResistanceExtension Target - careplusvn.com
Organon & Co stock hits 52-week high at $13.78 By Investing.com - Investing.com Nigeria
Organon & Co stock hits 52-week high at $13.78 - Investing.com India
Henlius - henlius.com
Organon earnings up next: Can drugmaker rebound after Q1 miss? - investing.com
Organon (OGN) Move: Ends Up by 0.07% at $13.74 on the Day; Technical Setup: the $13.05 to $14.43 Range Remains in FocusBox Spread - Vinanet
Sun Pharma completes $11.75bn financing syndication for Organon acquisition - Generics and Biosimilars Initiative
Organon (OGN) Trading: Ends Up by 0.37% at $13.73 at the Close; Next Session: the Supplied Trading Band Runs From $13.04 to $14.42 under the Current SnapshotOvernight Profile - Vinanet
Organon & Co stock hits 52-week high at 13.73 USD - Investing.com
Organon & Co. (NYSE:OGN) Reaches New 12-Month HighStill a Buy? - MarketBeat
Orographic Financial Advisors, LLC's Organon & Co(OGN) Holding History - GuruFocus
how InvestingPro’s Fair Value spotted Organon’s 69% gain potential By Investing.com - Investing.com South Africa
Organon (OGN): Pentwater Capital discloses 18.1M-share, 6.9% ownership stake - Stock Titan
Kevin Hern sells stocks in Organon & Co. and Versant Media Group - Investing.com Nigeria
Kevin Hern sells stocks in Organon & Co. and Versant Media Group By Investing.com - Investing.com Australia
This House of Representative Just Sold Up To $30K In Organon Stock - Benzinga
Organon & Co To Go Ex-Dividend On August 14th, 2026 With 0.02 USD Dividend Per Share - 富途牛牛
Organon & Co. (NYSE:OGN) Reaches New 1-Year HighShould You Buy? - MarketBeat
Sei Investments Co. Has $1.14 Million Holdings in Organon & Co. $OGN - MarketBeat
Organon Co Stock (OGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):